Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review.
Dizziness and ataxia
Management of adverse events
TRK inhibitors
Weight gain
Withdrawal-associated pain
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
17
01
2022
accepted:
07
10
2022
pubmed:
4
11
2022
medline:
6
12
2022
entrez:
3
11
2022
Statut:
ppublish
Résumé
The aim of this article is to conduct a literature review on first-generation TRK inhibitors (TRKi), namely entrectinib and larotrectinib, to describe the most common adverse events (AEs) and their management in adults. A search strategy was conducted in MEDLINE, EMBASE, and Google Scholar using a list of predetermined keywords. Peer-reviewed articles written in English and published through June 2021 were included. Articles covered included randomized clinical trials and expert recommendations, as well as patent and other types of reviews. The discussed AEs include weight gain and withdrawal pain, as well as neuromuscular, central nervous system (dysesthesias and peripheral sensory neuropathies, dizziness and ataxia, and dysgeusia), gastrointestinal (nausea, vomiting, and diarrhea), and respiratory symptoms. Additionally, several AEs encountered with entrectinib specifically (cognitive and vision disorders, congestive heart failure, QTc elongation, and skeletal fractures) are discussed. First, an overall mechanism of action explaining these AEs is presented. Then, for each AE, incidence and severity are stated and followed by practical management recommendations. While nearly all AEs were reversible upon TRKi suspension, the proposed managements are mainly constituted of pharmacological and non-pharmacological interventions. With the estimated growth of gene sequencing in the coming years, it is foreseeable that TRKi will take a larger position in the oncologic therapeutic arsenal. Therefore, adequate management of AEs associated with TRKi in adults should be a prime focus.
Identifiants
pubmed: 36326907
doi: 10.1007/s00520-022-07401-y
pii: 10.1007/s00520-022-07401-y
doi:
Substances chimiques
entrectinib
L5ORF0AN1I
tyrosine receptor
0
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
10471-10482Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Cocco E, Scaltriti M, Drilon A et al (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731–747
doi: 10.1038/s41571-018-0113-0
pubmed: 30333516
pmcid: 6419506
Demetri GD, Antonescu CR, Bjerkehagen B et al (2020) Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol 11:1506–1517
doi: 10.1016/j.annonc.2020.08.2232
Bailey JJ, Jaworski C, Tung D et al (2020) Tropomyosin receptor kinase inhibitors: an updated patent review for 2016–2019. Expert Opin Ther Pat 5:325–339
doi: 10.1080/13543776.2020.1737011
Kummar S, Lassen UN (2018) TRK inhibition: a new tumor-agnostic treatment strategy. Target Oncol 13:545–556
doi: 10.1007/s11523-018-0590-1
pubmed: 30276762
Lassen U (2019) How I treat NTRK gene fusion-positive cancers. ESMO Open 4(Suppl 2):1–3
Perreault S, Chami R, Deyell RJ et al (2021) Canadian consensus for biomarker testing and treatment of TRK fusion cancer in pediatric patients. Curr Oncol 28:346–366
doi: 10.3390/curroncol28010038
pubmed: 33435412
pmcid: 7903261
Bebb DG, Banerji S, Blais N et al (2021) Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. Curr Oncol 28:523–548
doi: 10.3390/curroncol28010053
pubmed: 33467570
pmcid: 7903287
Liu D, Flory J, Lin A et al (2020) Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann Oncol 9:1207–1215
doi: 10.1016/j.annonc.2020.05.006
Lim JSJ, Tan DSP (2020) TRK inhibitors-managing on-target toxicities. Ann Oncol 20:39897–39905
OnTarget. Available at https://ontargetonco.com/ . Accessed May 13, 2021
Doebele RC, Drilon A, Paz-Ares L et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 21:271–282
doi: 10.1016/S1470-2045(19)30691-6
pubmed: 31838007
Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378:731–739
doi: 10.1056/NEJMoa1714448
pubmed: 29466156
pmcid: 5857389
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Available at https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf . Accessed May 13, 2021
Drilon A (2019) TRK inhibitors in TRK fusion-positive cancers. Ann Oncol 20(suppl 8):23–30
doi: 10.1093/annonc/mdz282
Hovan AJ, Williams PM, Stevenson-Moore P et al (2010) A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 18:1081–1087
doi: 10.1007/s00520-010-0902-1
pubmed: 20495984
Hoffman-La Roche Limited. Product monograph including patient medication information: Rozlytrek. Available at https://www.rochecanada.com/content/dam/rochexx/roche-ca/products/ConsumerInformation/MonographsandPublicAdvisories/Rozlytrek/Rozlytrek_PM_E.pdf . Accessed May 13, 2021
U.S. Food and Drug Administration. Prescribing information: Rozlytrek. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf . Accessed May 13, 2021
Bayer Inc. Product monograph including patient medication information: Vitrakvi. Available at https://omr.bayer.ca/omr/online/vitrakvi-pm-en.pdf . Accessed May 13, 2021
U.S. Food and Drug Administration. Prescribing information: Vitrakvi. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf . Accessed May 13, 2021
Loprinzi CL, Lacchetti C, Bleeker J et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38:3325–3345
doi: 10.1200/JCO.20.01399
pubmed: 32663120
Timmins HC, Mizrahi D, Li T et al (2021) Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. J Cancer Surviv. Abstract s11764–021–00988-x
Fife K, Herd R, Lalondrelle S et al (2017) Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma. Future Oncol 13:175–184
doi: 10.2217/fon-2016-0296
pubmed: 27640448
Moore KN, Monk BJ (2016) Patient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancer. Oncologist 21:954–963
doi: 10.1634/theoncologist.2015-0268
pubmed: 27256873
pmcid: 4978548
Paz-Ares L, Barlesi F, Siena S et al (2021) Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. ESMO Open 6:100–113
doi: 10.1016/j.esmoop.2021.100113
Hesketh PJ, Kris MG, Basch E, et al (2020) Antiemetics: ASCO Guideline Update. J Clin Oncol 38(24):2782–2797. https://doi.org/10.1200/JCO.20.01296
U.S. Food and Drug Administration. Prescribing information: Akynzeo. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210493s000lbl.pdf . Accessed May 28, 2021
Bossi P, Antonuzzo A, Cherny NI et al (2018) Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 29(Suppl 4):126–142
doi: 10.1093/annonc/mdy145
Yancy CW, Jessup M, Bozkurt B et al (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. Circulation 136:137–161
doi: 10.1161/CIR.0000000000000509
European Society for Medical Oncology. ESMO Clinical Practice Guidelines: supportive and palliative care. Available at https://www.esmo.org/guidelines/supportive-and-palliative-care . Accessed June 11, 2021
Harvard T.H. Chan School of Public Health. Obesity prevention source. Available at https://www.hsph.harvard.edu/obesity-prevention-source/obesity-causes/diet-and-weight/ . Accessed June 11, 2021
Powell-Wiley TM, Poirier P, Burke LE et al (2021) Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 143:984–1010
doi: 10.1161/CIR.0000000000000973
American Society of Clinical Oncology (ASCO). Joint pain. Available at https://www.cancer.net/coping-with-cancer/physical-emotional-and-social-effects-cancer/managing-physical-side-effects/joint-pain . Accessed June 8, 2021
BreastCancer.org. Muscle Pain (Myalgia). Available at https://www.breastcancer.org/treatment/side_effects/muscle_pain . Accessed June 8, 2021
ESMO (2018) Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 29 (Suppl 4): 126–142.
BC Cancer Agency. Symptom management guidelines: pain. Available at http://www.bccancer.bc.ca/nursing-site/Documents/13.%20Pain.pdf . Accessed June 4, 2021
Jordan B, Margulies A, Cardoso F et al (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 31:1306–1319
doi: 10.1016/j.annonc.2020.07.003
pubmed: 32739407
Sartore-Bianchi A, Pizzutilo EG, Marrapese G et al (2020) Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. Expert Rev Anticancer Ther 20:333–341
doi: 10.1080/14737140.2020.1747439
pubmed: 32223357
BC Cancer. Problems with balance and coordination. Available at http://www.bccancer.bc.ca/managing-symptoms-site/Documents/Balance-and-Coordination.pdf . Accessed May 19, 2021
Federman N, McDermott R (2019) Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer. Expert Rev Clin Pharmacol 12:931–939
doi: 10.1080/17512433.2019.1661775
pubmed: 31469968
Lacouture ME, Dréno B, Ascierto PA et al (2016) Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist 21:1218–1229
doi: 10.1634/theoncologist.2016-0186
pubmed: 27511905
pmcid: 5061532
BC Cancer Agency. Nutritional guidelines for symptom management: taste changes. Available at http://www.bccancer.bc.ca/nutrition-site/Documents/Symptom%20management%20guidelines/TasteChanges.pdf . Accessed May 26, 2021
Scott LJ (2019) Larotrectinib: first global approval. Drugs 79:201–206
doi: 10.1007/s40265-018-1044-x
pubmed: 30635837
National Comprehensive Cancer Network. NCCN guidelines – supportive care. Available at nccn.org/guidelines/category_3 . Accessed June 11, 2021
U.S. Food and Drug Administration. Prescribing information: Varubi. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206500s000lbl.pdf . Accessed May 28, 2021
Andreyev J, Ross P, Donnellan C et al (2014) Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol 15:447–460
doi: 10.1016/S1470-2045(14)70006-3
Stein A, Voigt W, Jordan K (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2:51–63
doi: 10.1177/1758834009355164
pubmed: 21789126
pmcid: 3126005
Hong DS, Bauer TM, Lee JJ et al (2019) Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol 30:325–331
doi: 10.1093/annonc/mdy539
pubmed: 30624546
pmcid: 6386027
Hong DS, DuBois SG, Kummar S et al (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase ½ clinical trials. Lancet Oncol 21:531–540
doi: 10.1016/S1470-2045(19)30856-3
pubmed: 32105622
pmcid: 7497841